Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.

Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets